Study Overview: This study is testing a new medicine called Farletuzumab Ecteribulin (also known as MORAb-202). The medicine is designed to target specific proteins found in some cancer cells. The study aims to understand how safe and effective this medicine is for people with certain types of cancer, including ovarian, endometrial, lung, and a specific type of breast cancer. The study will be conducted in three parts to find the best dose and see how well it works and is tolerated by patients.

• The study involves multiple visits over several months to monitor progress and adjust doses.
• Participants will be monitored for any side effects and how their cancer responds to the treatment.
• There are specific health and medical history requirements to join the study.

This study could help find new treatments for tough-to-treat cancers. Participants will receive care and follow-up from medical professionals throughout the study. If you meet the eligibility criteria and are interested, you might consider participating. Always discuss with your doctor before joining any clinical study.